Phrenix Therapeutics Pty Ltd
Phrenix Therapeutics is developing new therapeutics for cognitive disorders, particularly in schizophrenia. The current targets are GPR52 agonists.
Year established: 2022
Lead Researchers and Co-Founders: Chris Langmead, Greg Stewart and Jess Nithianantharajah
Twitter: twitter.com/PhrenixTx